Inventiva SA (IVA) Stock Analysis
Verdict: AVOID
Severe cash burn ($105M/yr) and dilution offset Lanifibranor potential — cash runway depletion dominates the near-term risk.
Investment score: 24/100
Analysis as of
Is Inventiva SA stock worth reviewing? The TradeMates thesis
Inventiva faces existential financial stress characterized by negative balance sheet equity (-$28.52M in 2025), a persistent annual cash burn (-$105.13M FCF in 2025), and a cash reserve of $99.31M that provides less than 12 months of operational runway. Rapid dilution has expanded shares outstanding from 41.45M in 2022 to 186.80M in 2025.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 50/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
Inventiva SA opportunities and risks
What speaks for IVA
- Lanifibranor Phase III NASH trial readout
What speaks against IVA
- Imminent cash depletion within 11 months
Frequently asked questions about Inventiva SA (IVA)
Is IVA stock a good investment?
The TradeMates model rates Inventiva SA as AVOID with an investment score of 24/100. Inventiva faces existential financial stress characterized by negative balance sheet equity (-$28.52M in 2025), a persistent annual cash burn (-$105.13M FCF in 2025), and a cash reserve of $99.31M that provides less than 12 months of operational runway. Rapid dilution has expanded shares outstanding from 41.45M in 2022 to 186.80M in 2025. This is algorithmic model output, not personal investment advice.
Is IVA stock a buy?
The TradeMates model verdict for IVA is AVOID with an investment score of 24/100. Treat this as a model signal to review, not a personal buy recommendation.